Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
This article was originally published in The Pink Sheet Daily
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority.
You may also be interested in...
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
In this periodic feature, PharmAsia News highlights recent analyst notes with a unique viewpoint on Asia or other emerging markets. The previous issue appeared in PharmAsia News, June 14, 2011.
DNDi Mulls Expansion Of India Site; Set To Team With More Pharma On The Heels Of Sanofi Deal - BIO Conference
WASHINGTON - Six years after establishing its India office, Geneva-based Drugs for Neglected Diseases Initiative (DNDi) is planning to expand its presence to cater to the drug development needs of the Indian population as well as neighboring countries like Bangladesh and Sri Lanka